Search research articles
Contact Us
Filters
Showing results (381-390 of 392) with videos related to
Page
of 40
Sort By:
JAMA Network Open
|
February 2, 2023
Clinical Importance of Clonal Hematopoiesis in Metastatic Gastrointestinal Tract Cancers
Bill H Diplas, Ryan Ptashkin, Joanne F Chou, et al.
JAMA Network Open
|
July 12, 2021
Prevalence of Germline Alterations on Targeted Tumor-Normal Sequencing of Esophagogastric Cancer
Geoffrey Y Ku, Yelena Kemel, Steve B Maron, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 3, 2019
Safety and Efficacy of Durvalumab and Tremelimumab Alone or in Combination in Patients with Advanced Gastric and Gastroesophageal Junction Adenocarcinoma
Ronan J Kelly, Jeeyun Lee, Yung-Jue Bang, et al.
Cancer
|
August 5, 2021
Pancreas cancer and BRCA: A critical subset of patients with improving therapeutic outcomes
Parisa Momtaz, Catherine A O'Connor, Joanne F Chou, et al.
The Lancet. Oncology
|
May 22, 2020
First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial
Yelena Y Janjigian, Steven B Maron, Walid K Chatila, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 29, 2022
Epidermal Growth Factor Receptor Inhibition in Epidermal Growth Factor Receptor-Amplified Gastroesophageal Cancer: Retrospective Global Experience
Steven B Maron, Stephanie Moya, Federica Morano, et al.
JCO Precision Oncology
|
April 22, 2026
Targeted Molecular Profiling of Circulating Cell-Free DNA in Patients With Gastroesophageal Adenocarcinoma
Samuel L Cytryn, Raktim Borpatragohain, Karmelina Charalambous, et al.
The Lancet. Oncology
|
September 4, 2023
First-line regorafenib with nivolumab and chemotherapy in advanced oesophageal, gastric, or gastro-oesophageal junction cancer in the USA: a single-arm, single-centre, phase 2 trial
Samuel L Cytryn, Ryan H Moy, Darren Cowzer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 22, 2024
Immune checkpoint inhibitors for POLE or POLD1 proofreading-deficient metastatic colorectal cancer
M Ambrosini, B Rousseau, P Manca, et al.
Cancer Discovery
|
November 23, 2018
<i>EGFR</i> and <i>MET</i> Amplifications Determine Response to HER2 Inhibition in <i>ERBB2</i>-Amplified Esophagogastric Cancer
Francisco Sanchez-Vega, Jaclyn F Hechtman, Pau Castel, et al.
Page
of 40
Search research articles
Search
Showing results (381-390 of 392) with videos related to
Sort By:
Page
of 40
JAMA Network Open
|
February 2, 2023
Clinical Importance of Clonal Hematopoiesis in Metastatic Gastrointestinal Tract Cancers
Bill H Diplas, Ryan Ptashkin, Joanne F Chou, et al.
JAMA Network Open
|
July 12, 2021
Prevalence of Germline Alterations on Targeted Tumor-Normal Sequencing of Esophagogastric Cancer
Geoffrey Y Ku, Yelena Kemel, Steve B Maron, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 3, 2019
Safety and Efficacy of Durvalumab and Tremelimumab Alone or in Combination in Patients with Advanced Gastric and Gastroesophageal Junction Adenocarcinoma
Ronan J Kelly, Jeeyun Lee, Yung-Jue Bang, et al.
Cancer
|
August 5, 2021
Pancreas cancer and BRCA: A critical subset of patients with improving therapeutic outcomes
Parisa Momtaz, Catherine A O'Connor, Joanne F Chou, et al.
The Lancet. Oncology
|
May 22, 2020
First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial
Yelena Y Janjigian, Steven B Maron, Walid K Chatila, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 29, 2022
Epidermal Growth Factor Receptor Inhibition in Epidermal Growth Factor Receptor-Amplified Gastroesophageal Cancer: Retrospective Global Experience
Steven B Maron, Stephanie Moya, Federica Morano, et al.
JCO Precision Oncology
|
April 22, 2026
Targeted Molecular Profiling of Circulating Cell-Free DNA in Patients With Gastroesophageal Adenocarcinoma
Samuel L Cytryn, Raktim Borpatragohain, Karmelina Charalambous, et al.
The Lancet. Oncology
|
September 4, 2023
First-line regorafenib with nivolumab and chemotherapy in advanced oesophageal, gastric, or gastro-oesophageal junction cancer in the USA: a single-arm, single-centre, phase 2 trial
Samuel L Cytryn, Ryan H Moy, Darren Cowzer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 22, 2024
Immune checkpoint inhibitors for POLE or POLD1 proofreading-deficient metastatic colorectal cancer
M Ambrosini, B Rousseau, P Manca, et al.
Cancer Discovery
|
November 23, 2018
<i>EGFR</i> and <i>MET</i> Amplifications Determine Response to HER2 Inhibition in <i>ERBB2</i>-Amplified Esophagogastric Cancer
Francisco Sanchez-Vega, Jaclyn F Hechtman, Pau Castel, et al.
Page
of 40